<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122630">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01823172</url>
  </required_header>
  <id_info>
    <org_study_id>12-009929</org_study_id>
    <nct_id>NCT01823172</nct_id>
  </id_info>
  <brief_title>Second Echelon Node Study With Methylene Blue</brief_title>
  <official_title>Feasibility of Lymphatic Mapping of Second Echelon Lymph Nodes With Methylene Blue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to study the ability to identify the lymph nodes beyond the sentinel
      lymph node that may harbor cancer using methylene blue dye.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The number of subjects in whom a secondary echelon lymph node is identified</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Methylene Blue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1% Methylene Blue - 1 ml. Methylene blue dye injection of sentinel lymph node</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Methylene blue dye injection of sentinel lymph node</intervention_name>
    <arm_group_label>Methylene Blue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed primary cutaneous melanoma located on the extremity or trunk

          -  Patients with clinically stage I-II melanoma

          -  Histologically confirmed invasive ductal or lobular carcinoma

          -  Patient undergoing surgical treatment of breast primary and sentinel lymph node
             biopsy- clinically node negative

        Exclusion Criteria:

          -  Melanoma located on the head or neck, uveal or mucosal

          -  Previous surgery or radiation in or near the sentinel lymph node bopsy nodal basin

          -  Preoperative biopsy proven regional lymph node involvement

          -  Failure of lymphatic mapping with radioactive colloid

          -  Women who are pregnant or nursing

          -  Prior ipsilateral axillary surgery or radiation

          -  Inflammatory breast cancer

          -  No lymph node identified in the ipsilateral breast during pathologic review of the
             mastectomy specimen

          -  Stage IV breast cancer
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Jakub, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>March 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>James W. Jakub</investigator_full_name>
    <investigator_title>Breast and Melanoma Surgery Section Head</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>melanoma</keyword>
  <keyword>sentinel lymph node biopsy</keyword>
  <keyword>lymphadenectomy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
